Wednesday, 21 Aug 2019

You are here

Statin Associated with an Increase in Inflammatory Myopathy

JAMA Internal Medicine reports that exposure to statin medications may be linked to histologically confirmed idiopathic inflammatory myositis.

A population-based, case-control study, using the South Australian Myositis Database, examined 221 patients with idiopathic inflammatory myositis (IIM) matched 1:3 with 662 controls. The 221 IIM cases had a mean age of 62.2 years, and 132 (59.7%) were female

Statin exposure at the time of IIM diagnosis was seen in 30.8% of the IIM patients  and 21.5% of controls (P = .005). There was a statistically significant 79% increased risk of idiopathic inflammatory myositis cases in those exposed to a statin drug  compared with controls (adjusted odds ratio, 1.79; 95% CI, 1.23-2.60; P = .001). 

The CDC estimates nearly 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia use a cholesterol-lowering. While myalgias are common,  but myopathy occurs in less than 1% and rhabdomyolysis and necrotizing myositis are very rare.  A NEJM article has shown that autoantibodies against 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and is estimated to occur in approximately 2 or 3 of every 100,000 patients treated with statins.  

 

 

 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.